COST-EFFECTIVENESS OF SECOND-LINE VASOPRESSORS FOR THE TREATMENT OF SEPTIC SHOCK

被引：0
|
作者：
Lam, Simon [1 ]
Barreto, Erin [2 ]
Scott, Rachael [3 ]
Kashani, Kianoush [3 ]
Khanna, Ashish [4 ]
Bauer, Seth [5 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] St Marys Hosp, Mayo Clin, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
[4] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[5] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
CRITICAL CARE MEDICINE | 2020年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
1630
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of second-line vasopressors for the treatment of septic shock
    Lam, Simon W.
    Barreto, Erin F.
    Scott, Rachael
    Kashani, Kianoush B.
    Khanna, Ashish K.
    Bauer, Seth R.
    JOURNAL OF CRITICAL CARE, 2020, 55 : 48 - 55
  • [2] Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain
    Peral, Carmen
    Cordido, Fernando
    Gimeno-Ballester, Vicente
    Mir, Nuria
    Sanchez-Cenizo, Laura
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (01) : 105 - 114
  • [3] Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma
    Soto-Perez-de-Celis, Enrique
    Aguiar, Pedro N., Jr.
    Cordon, Monica L.
    Chavarri-Guerra, Yanin
    Lopes, Gilberto de Lima, Jr.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06): : 669 - 675
  • [4] COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA
    Kobelt, G.
    Lindgren, P.
    VALUE IN HEALTH, 2008, 11 (06) : A548 - A548
  • [5] Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
    Hoyle, Martin
    Green, Colin
    Thompson-Coon, Jo
    Liu, Zulian
    Welch, Karen
    Moxham, Tiffany
    Stein, Ken
    VALUE IN HEALTH, 2010, 13 (01) : 55 - 60
  • [6] Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
    Chiang, Chi-leung
    Chan, Sik-kwan
    Lee, Shing-fung
    Wong, Irene Oi-ling
    Choi, Horace Cheuk-wai
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [7] Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer
    Sarfaty, Michal
    Hall, Peter
    Chan, Kelvin K.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [8] Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
    Sarfaty, Michal
    Hall, Peter S.
    Chan, Kelvin K. W.
    Virik, Kiran
    Leshno, Moshe
    Gordon, Noa
    Moore, Assaf
    Neiman, Victoria
    Rosenbaum, Eli
    Goldstein, Daniel A.
    EUROPEAN UROLOGY, 2018, 74 (01) : 57 - 62
  • [9] A COST-EFFECTIVENESS STUDY OF SECOND-LINE TREATMENT IN PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER IN SPAIN
    Arlandis, S.
    Castro, D.
    Errando, C.
    Fernandez, E.
    Jimenez, M.
    Gonzalez, P.
    Crespo, C.
    Stauble, F.
    Rodriguez, J. M.
    GACETA SANITARIA, 2009, 23 : 200 - 201
  • [10] COST-EFFECTIVENESS ANALYSIS OF FULVESTRANT IN THE TREATMENT OF METASTATIC BREAST CANCER IN SECOND-LINE CHEMOTHERAPY
    Krysanov, I
    Krysanova, V
    VALUE IN HEALTH, 2014, 17 (07) : A637 - A637
12345